Differences in patient- and tumor characteristics, treatment and survival between patients with screen-detected versus clinically detected colorectal peritoneal metastases
- 25 October 2024
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (1) , 108789
Abstract
No abstract availableKeywords
Funding Information
- Roche
This publication has 10 references indexed in Scilit:
- Initial Impact of National CRC Screening on Incidence and Advanced Colorectal CancerClinical Gastroenterology and Hepatology, 2022
- Patterns and Timing of Recurrence following CRS and HIPEC in Colorectal Cancer Peritoneal MetastasisEuropean Journal of Surgical Oncology, 2022
- Global colorectal cancer burden in 2020 and projections to 2040Translational Oncology, 2021
- Estimates of stage-specific preclinical sojourn time across 21 cancer types.Journal of Clinical Oncology, 2021
- Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the ChallengesFrontiers in Oncology, 2021
- Diagnosis and Treatment of Metastatic Colorectal CancerJAMA, 2021
- Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population‐based analysisCancer Medicine, 2019
- Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off LevelsGastroenterology, 2017
- Length time bias in surveillance for hepatocellular carcinoma and how to avoid itHepatology Research, 2016
- Correcting for Lead Time and Length Bias in Estimating the Effect of Screen Detection on Cancer SurvivalAmerican Journal of Epidemiology, 2008